World Health Organization. Genes and human disease. http://www.who.int/genomics/public/geneticdiseases/en/index2.html. Accessed 22 March 2015.
Central Intelligence Agency. The World Factbook. 2016. https://www.cia.gov/library/publications/the-world-factbook/geos/xx.html; Accessed 22 March 2018.
Rabbani B, Tekin M & Mahdieh N. The promise of whole-exome sequencing in medical genetics. J Hum Genet 2014;59:5–15.
Shashi V, McConkie-Rosell A, Rosell B et al. The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders. Genet Med 2014;16:176–182.
Bamshad MJ, Ng SB, Bigham AW et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet 2011;12:745–755.
Gilissen C, Hoischen A, Brunner HG & Veltman JA. Unlocking Mendelian disease using exome sequencing. Genome 2011;11:64.
Rabbani B, Mahdieh N, Hosomichi K, Nakaoka H & Inoue I. Next-generation sequencing: impact of exome sequencing in characterizing Mendelian disorders. J Hum Genet 2012;57:621–632.
Zhang X. Exome sequencing greatly expedites the progressive research of Mendelian diseases. Front Med 2014;8:42–57.
Jacob H, Abrams K, Bick D et al. Genomics in clinical practice: lessons from the front lines. Sci Transl Med 2013;5:194cm5.
Biesecker LG & Green RC. Diagnostic clinical genome and exome sequencing. N Engl J Med 2014;370:2418–2425.
Wenger AM, Guturu H, Bernstein JA & Bejerano G. Systematic reanalysis of clinical exome data yields additional diagnoses: implications for providers. Genet Med 2017;19:209–214.
Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM & Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 2014;46:310–315.
Paila U, Chapman BA, Kirchner R & Quinlan AR. GEMINI: integrative exploration of genetic variation and genome annotations. PLoS Comput Biol 2013;9:e1003153.
Choi Y & Chan AP. PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. Bioinformatics 2015;31:2745–2747.
Seelow D, Schuelke M, Hildebrandt F & Nurnberg P. Homozygosity Mapper—an interactive approach to homozygosity mapping. Nucleic Acids Res 2009;37:W593–W599.
Thorvaldsdottir H, Robinson JT & Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 2013;14:178–192.
Richards S, Aziz N, Bale S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405–423.
NSW Health. NSW Health Renumerations and Conditions. NSW Government Health. 2016. http://www.health.nsw.gov.au/careers/conditions/Pages/default.aspx; Accessed 22 March 2018.
Australian Government Department of Health. Medicare Benefits Schedule Book. April 2014. http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/Home; Accessed 22 March 2018.
Denayer E, Parret A, Chmara M et al. Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation. Hum Mutat 2008;29:232–239.
Loveday C, Tatton-Brown K, Clarke M et al. Mutations in the PP2A regulatory subunit B family genes PPP2R5B
PPP2R5C and PPP2R5D cause human overgrowth. Hum Mol Genet 2015;24:4775–4779.
Kremer LS, Distelmaier F, Alhaddad B et al. Bi-allelic truncating mutations in TANGO2 cause infancy-onset recurrent metabolic crises with encephalocardiomyopathy. Am J Hum Genet 2016;98:358–362.
Lalani SR, Liu P, Rosenfeld JA et al. Recurrent muscle weakness with rhabdomyolysis, metabolic crises, and cardiac arrhythmia due to bi-allelic TANGO2 mutations. Am J Hum Genet 2016;98:347–357.
Gilissen C, Hehir-Kwa JY, Thung DT et al. Genome sequencing identifies major causes of severe intellectual disability. Nature 2014;511:344–347.
Soden SE, Saunders CJ, Willig LK et al. Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders. Sci Transl Med 2014;6:265ra168.
Yang Y, Muzny DM, Reid JG et al. Clinical whole-exome sequencing for the diagnosis of Mendelian disorders. N Engl J Med 2013;369:1502–1511.
Farwell KD, Shahmirzadi L, El-Khechen D et al. Enhanced utility of family-centered diagnostic exome sequencing with inheritance model–based analysis: results from 500 unselected families with undiagnosed genetic conditions. Genet Med 2015;17:578–586.
Lazaridis KN, Schahl KA, Cousin MA et al. Outcome of whole exome sequencing for diagnostic odyssey cases of an individualized medicine clinic. Mayo Clin Proc 2016;91:297–307.
Retterer K, Juusola J, Cho MT et al. Clinical application of whole-exome sequencing across clinical indications. Genet Med 2016;18:696–704.
Kassahn KS, Scott HS & Caramins MC. Integrating massively parallel sequencing into diagnostic workflows and managing the annotation and clinical interpretation challenge. Hum Mutat 2014;35:413–423.
Lee H, Deignan JL, Dorrani N et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. JAMA 2014;312:1880.
Choi M, Scholl UI, Ji W et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci USA 2009;106:19096–19101.
Majewski J, Wang Z, Lopez I et al. A new ocular phenotype associated with an unexpected but known systemic disorder and mutation: novel use of genomic diagnostics and exome sequencing. J Med Genet 2011;48:593–596.
Zhan Z, Liao X, Du J et al. Exome sequencing released a case of X-linked adrenoleukodystrophy mimicking recessive hereditary spastic paraplegia. Eur J Med Genet 2013;56:375–378.
Sawyer SL, Hartley T, Dyment DA et al. Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care: whole-exome sequencing for rare disease diagnosis. Clin Genet 2016;89:275–284.
Kleefstra T, Wortmann S, Rodenburg R et al. Mitochondrial dysfunction and organic aciduria in five patients carrying mutations in the Ras-MAPK pathway. Eur J Hum Genet 2011;19:138–144.
Stark Z, Schofield D, Alam K et al. Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement. Genet Med 2017;19:867–874.
Doran CM, Einfeld SL, Madden RH et al. How much does intellectual disability really cost? First estimates for Australia. J Intellect Dev Disabil 2012;37:42–49.
Belkadi A, Bolze A, Itan Y et al. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants. Proc Natl Acad Sci USA 2015;112:5473–5478.
Eldomery MK, Coban-Akdemir Z, Harel T et al. Lessons learned from additional research analyses of unsolved clinical exome cases. Genome Med 2017;9:26.